30 closest matches · ranked by relevance
Recurrent Uterine Corpus Sarcoma · Uterine Carcinosarcoma
Primary: Progression-free Survival (PFS) > 6 Months — 17.8 percentage of participants
Sarcoma
Primary: Number of Patients With Objective Tumor Response Rate (Complete Response [CR] or Partial Response [PR]) Using RECIST Version 1.0 — 2; 0 participants
Leiomyosarcoma · Uterine Neoplasm
Primary: Two-year Progression-free Survival Among Women Treated With This Adjuvant Regimen for High Risk Uterine LMS — 78 percentage of participants — p=0.15
Recurrent Uterine Corpus Sarcoma · Uterine Corpus Leiomyosarcoma
Primary: Progression-free Survival (PFS) > 6 Months — 0.0 percentage of participants
Recurrent Uterine Sarcoma · Uterine Carcinosarcoma
Primary: Progression-free Survival (PFS) > 6 Months — 4.3 percentage of participants
Recurrent Uterine Sarcoma · Stage III Uterine Sarcoma · Stage IV Uterine Sarcoma
Primary: Objective Overall Response Rate — 2; 0 participants
Uterine Cancer
Primary: To Evaluate the Toxicity and Tolerability of Pelvic Radiation "Sandwiched" Between Cycles of Paclitaxel/Carboplatin Chemotherapy in Patients With UPSC — 65.5; 25.8…
Recurrent Uterine Corpus Sarcoma · Uterine Corpus Leiomyosarcoma
Primary: Tumor Response — 0 percentage of participants
Recurrent Uterine Corpus Sarcoma · Uterine Carcinosarcoma
Primary: Objective Tumor Response (Complete or Partial) — 0 percentage of participants
Recurrent Uterine Corpus Sarcoma · Uterine Carcinosarcoma
Primary: Objective Tumor Response — 11.8 percentage
Carcinosarcoma, Ovarian
Primary: Proportion of Patients With Completion of 4 Cycles of CT + GB — 0.7826 proportion of patients
Recurrent Uterine Corpus Sarcoma · Uterine Carcinosarcoma
Primary: Percentage of Patients With Objective Tumor Response Rate (Either Complete Response (CR) or Partial Response (PR) Using RECIST Version 1.0 — 8 Percentage of participants
Endometrial Cancer
Primary: Overall Survival at 2 Years and 5 Years — 93; 85 percentage of participants
Uterine Cancer
Primary: Cycles With Hematologic Toxicities — 11; 14; 6; 0 Cycles
Sarcoma
Primary: Nature and Degree of Toxicity — 2; 4; 20; 19 Participants
Leiomyosarcoma
Primary: Progression Free Survival Rate at 12 Weeks — 46 percentage of participants
Metastatic Leiomyosarcoma · Unresectable Leiomyosarcoma · Uterine Corpus Leiomyosarcoma
Primary: Objective Response Per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 Among Patients With Advanced Leiomyosarcoma of the Uterus (ULMS) Treated With Nivolumab…
Endometrial Cancer
Primary: Progression Free Survival Differences Between Treatment Arms. — 8.049; 12.945 months
Endometrial Adenocarcinoma · Endometrial Endometrioid Adenocarcinoma · Endometrial Serous Adenocarcinoma
Primary: Objective Response Rate — 6; 6; 16; 5 Participants
Uterine Serous Carcinoma
Primary: Objective Response Rate (ORR) — 26 Percentage of participants
Endometrial Adenocarcinoma · Endometrial Adenosquamous Carcinoma · Endometrial Clear Cell Adenocarcinoma
Primary: Number of Participants With or Without Progression-free Survival for > 6 Months by Response Evaluation Criteria for Solid Tumors (RECIST) — 39; 11 participants
Osteosarcoma · Ewing Sarcoma · Rhabdomyosarcoma
Primary: Response Rate — 15.3 percentage of participants
Borderline Ovarian Serous Tumor · Low Grade Ovarian Serous Adenocarcinoma · Micropapillary Serous Carcinoma
Primary: Tumor Response — 15.4 percentage of patients
Sarcoma
Primary: Number of Patients With Dose Limiting Toxicities. — 0; 1; 0 Participants
Endometrial Adenocarcinoma · Endometrial Clear Cell Adenocarcinoma · Endometrial Mixed Adenocarcinoma
Primary: Response — 0 percentage of participants
Malignant Ovarian Epithelial Tumor · Ovarian Granulosa Cell Tumor · Ovarian Gynandroblastoma
Primary: Tumor Response — 16.7 percentage of patients
Endometrial Cancer
Primary: Number of Participants With Objective Response Plus Stable Disease Rate (CR + PR + SD) — 0; 0; 14; 17 participants
Endometrial Cancer · Recurrent Endometrial Cancer
Primary: Clinical Benefit Rate (CBR) — 7; 18 Participants
Epithelial Ovarian Cancer · Fallopian Tube Cancer · Primary Peritoneal Cancer
Primary: Phase 1b: Recommended Phase 2 Dose of LY2228820 in Combination With Gemcitabine and Carboplatin (Maximum Tolerated Dose [MTD]) — 200 milligrams (mg)
Metastatic Endometrial Cancer
Primary: Progression Free Survival (PFS) — 28.1; 8.7 months